Fig. 2From: Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database studyPatient Identification Flowcharta. aAssociated with a migraine diagnosis ≤14 days post the first migraine diagnosis between 01-May-2018 and 30-Sep-2019.b OnabotulinumtoxinA use requires a migraine diagnosis at most 14 days before claim and days-of-supply ≥28 days. CGRP, calcitonin gene-related peptideBack to article page